Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10
The kinetic impact of intestinal glucuronidation metabolism on oral bioavailability ( F) was assessed using reported human data of raloxifene, of which oral bioavailability was only 2%. Kinetic analysis showed that presystemic intestinal availability (Fpg) was 5.4%, whereas fraction absorbed (Ff) an...
Gespeichert in:
| Veröffentlicht in: | International journal of pharmaceutics 2009-08, Vol.378 (1), p.140-141 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 141 |
|---|---|
| container_issue | 1 |
| container_start_page | 140 |
| container_title | International journal of pharmaceutics |
| container_volume | 378 |
| creator | Mizuma, Takashi |
| description | The kinetic impact of intestinal glucuronidation metabolism on oral bioavailability (
F) was assessed using reported human data of raloxifene, of which oral bioavailability was only 2%. Kinetic analysis showed that presystemic intestinal availability (Fpg) was 5.4%, whereas fraction absorbed (Ff) and hepatic availability (Fh) were 63% and 59.3%, respectively. Thus, Fpg was the lowest among factors, which affect oral bioavailability. In addition, Fpg was much lower than Fh, suggesting that intestinal glucuronidation metabolism has a greater impact on oral bioavailability than hepatic glucuronidation metabolism. It has been reported that UDP-glucuronosyltransferase (UGT) 1A1, UGT1A8, UGT1A9, and UGT1A10 are enzymes for raloxifene glucuronidation, and UGT1A8 and UGT1A10 are absent in the human liver, whereas UGT1A1, UGT1A8, UGT1A9, and UGT1A10 are present in the human intestine. Therefore, it is also suggested that intestinal glucuronidation catalyzed by UGTs, particularly UGT1A8 and UGT1A10, may play important roles in the first-pass metabolism, causing low oral bioavailability. |
| doi_str_mv | 10.1016/j.ijpharm.2009.05.044 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733570991</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517309003536</els_id><sourcerecordid>733570991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-9a9a394df0e0fcb6d376ba68047fb4fedcd6dca2b7d792bb2ad31ce45c68346a3</originalsourceid><addsrcrecordid>eNqFkcFuEzEQhlcIREvhEUC-IC5JsNe79i6XKqqgVKrEpT1bY3u2cbRrB9sbyDvyUDhKBDe4zMzh-_8ZzV9VbxldMcrEx-3KbXcbiNOqprRf0XZFm-ZZdck6yZe8keJ5dUm57JYtk_yiepXSllIqasZfVhesbzrR8-ay-nXnM6bsPIzkaZzNHIN3FrILnkyYQYfRpYlMcCAb2CMB8hQRMkbiph2YTAoXYhFrF2APbgTtRpcPJG_Akw3uipX5l7Mr1DyBT5_ImqQ82wP54fKGFM_w0w3ocUHSrFOOZSsZQiSPtw9szRaErbtj6RcEvC0Do6-rFwOMCd-c-1X1-OXzw83X5f2327ub9f3S8L7Jyx56KIMdKNLBaGG5FBpERxs56GZAa6ywBmotrexrrWuwnBlsWiM63gjgV9WHk-8uhu9zeZ-aXDI4juAxzElJzltJ-54Vsj2RJoaUIg5qF90E8aAYVccc1Vadc1THHBVtVcmx6N6dN8x6QvtXdQ6uAO_PACQD4xDBG5f-cDXrairkkbs-cVj-sXcYVTIOvUHrIpqsbHD_OeU3EmnCOg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733570991</pqid></control><display><type>article</type><title>Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Mizuma, Takashi</creator><creatorcontrib>Mizuma, Takashi</creatorcontrib><description>The kinetic impact of intestinal glucuronidation metabolism on oral bioavailability (
F) was assessed using reported human data of raloxifene, of which oral bioavailability was only 2%. Kinetic analysis showed that presystemic intestinal availability (Fpg) was 5.4%, whereas fraction absorbed (Ff) and hepatic availability (Fh) were 63% and 59.3%, respectively. Thus, Fpg was the lowest among factors, which affect oral bioavailability. In addition, Fpg was much lower than Fh, suggesting that intestinal glucuronidation metabolism has a greater impact on oral bioavailability than hepatic glucuronidation metabolism. It has been reported that UDP-glucuronosyltransferase (UGT) 1A1, UGT1A8, UGT1A9, and UGT1A10 are enzymes for raloxifene glucuronidation, and UGT1A8 and UGT1A10 are absent in the human liver, whereas UGT1A1, UGT1A8, UGT1A9, and UGT1A10 are present in the human intestine. Therefore, it is also suggested that intestinal glucuronidation catalyzed by UGTs, particularly UGT1A8 and UGT1A10, may play important roles in the first-pass metabolism, causing low oral bioavailability.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2009.05.044</identifier><identifier>PMID: 19486934</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Administration, Oral ; Biological and medical sciences ; Biological Availability ; General pharmacology ; Glucuronidation metabolism ; Glucuronides - metabolism ; Glucuronosyltransferase - metabolism ; Humans ; Intestines - enzymology ; Intestines - metabolism ; Liver - enzymology ; Liver - metabolism ; Medical sciences ; Oral bioavailability ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Presystemic intestinal availability ; Presystemic metabolism ; Raloxifene Hydrochloride - pharmacokinetics ; Selective Estrogen Receptor Modulators - pharmacokinetics</subject><ispartof>International journal of pharmaceutics, 2009-08, Vol.378 (1), p.140-141</ispartof><rights>2009 Elsevier B.V.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c394t-9a9a394df0e0fcb6d376ba68047fb4fedcd6dca2b7d792bb2ad31ce45c68346a3</citedby><cites>FETCH-LOGICAL-c394t-9a9a394df0e0fcb6d376ba68047fb4fedcd6dca2b7d792bb2ad31ce45c68346a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2009.05.044$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21820674$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19486934$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mizuma, Takashi</creatorcontrib><title>Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>The kinetic impact of intestinal glucuronidation metabolism on oral bioavailability (
F) was assessed using reported human data of raloxifene, of which oral bioavailability was only 2%. Kinetic analysis showed that presystemic intestinal availability (Fpg) was 5.4%, whereas fraction absorbed (Ff) and hepatic availability (Fh) were 63% and 59.3%, respectively. Thus, Fpg was the lowest among factors, which affect oral bioavailability. In addition, Fpg was much lower than Fh, suggesting that intestinal glucuronidation metabolism has a greater impact on oral bioavailability than hepatic glucuronidation metabolism. It has been reported that UDP-glucuronosyltransferase (UGT) 1A1, UGT1A8, UGT1A9, and UGT1A10 are enzymes for raloxifene glucuronidation, and UGT1A8 and UGT1A10 are absent in the human liver, whereas UGT1A1, UGT1A8, UGT1A9, and UGT1A10 are present in the human intestine. Therefore, it is also suggested that intestinal glucuronidation catalyzed by UGTs, particularly UGT1A8 and UGT1A10, may play important roles in the first-pass metabolism, causing low oral bioavailability.</description><subject>Administration, Oral</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>General pharmacology</subject><subject>Glucuronidation metabolism</subject><subject>Glucuronides - metabolism</subject><subject>Glucuronosyltransferase - metabolism</subject><subject>Humans</subject><subject>Intestines - enzymology</subject><subject>Intestines - metabolism</subject><subject>Liver - enzymology</subject><subject>Liver - metabolism</subject><subject>Medical sciences</subject><subject>Oral bioavailability</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Presystemic intestinal availability</subject><subject>Presystemic metabolism</subject><subject>Raloxifene Hydrochloride - pharmacokinetics</subject><subject>Selective Estrogen Receptor Modulators - pharmacokinetics</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFuEzEQhlcIREvhEUC-IC5JsNe79i6XKqqgVKrEpT1bY3u2cbRrB9sbyDvyUDhKBDe4zMzh-_8ZzV9VbxldMcrEx-3KbXcbiNOqprRf0XZFm-ZZdck6yZe8keJ5dUm57JYtk_yiepXSllIqasZfVhesbzrR8-ay-nXnM6bsPIzkaZzNHIN3FrILnkyYQYfRpYlMcCAb2CMB8hQRMkbiph2YTAoXYhFrF2APbgTtRpcPJG_Akw3uipX5l7Mr1DyBT5_ImqQ82wP54fKGFM_w0w3ocUHSrFOOZSsZQiSPtw9szRaErbtj6RcEvC0Do6-rFwOMCd-c-1X1-OXzw83X5f2327ub9f3S8L7Jyx56KIMdKNLBaGG5FBpERxs56GZAa6ywBmotrexrrWuwnBlsWiM63gjgV9WHk-8uhu9zeZ-aXDI4juAxzElJzltJ-54Vsj2RJoaUIg5qF90E8aAYVccc1Vadc1THHBVtVcmx6N6dN8x6QvtXdQ6uAO_PACQD4xDBG5f-cDXrairkkbs-cVj-sXcYVTIOvUHrIpqsbHD_OeU3EmnCOg</recordid><startdate>20090813</startdate><enddate>20090813</enddate><creator>Mizuma, Takashi</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090813</creationdate><title>Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</title><author>Mizuma, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-9a9a394df0e0fcb6d376ba68047fb4fedcd6dca2b7d792bb2ad31ce45c68346a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Administration, Oral</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>General pharmacology</topic><topic>Glucuronidation metabolism</topic><topic>Glucuronides - metabolism</topic><topic>Glucuronosyltransferase - metabolism</topic><topic>Humans</topic><topic>Intestines - enzymology</topic><topic>Intestines - metabolism</topic><topic>Liver - enzymology</topic><topic>Liver - metabolism</topic><topic>Medical sciences</topic><topic>Oral bioavailability</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Presystemic intestinal availability</topic><topic>Presystemic metabolism</topic><topic>Raloxifene Hydrochloride - pharmacokinetics</topic><topic>Selective Estrogen Receptor Modulators - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mizuma, Takashi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mizuma, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2009-08-13</date><risdate>2009</risdate><volume>378</volume><issue>1</issue><spage>140</spage><epage>141</epage><pages>140-141</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>The kinetic impact of intestinal glucuronidation metabolism on oral bioavailability (
F) was assessed using reported human data of raloxifene, of which oral bioavailability was only 2%. Kinetic analysis showed that presystemic intestinal availability (Fpg) was 5.4%, whereas fraction absorbed (Ff) and hepatic availability (Fh) were 63% and 59.3%, respectively. Thus, Fpg was the lowest among factors, which affect oral bioavailability. In addition, Fpg was much lower than Fh, suggesting that intestinal glucuronidation metabolism has a greater impact on oral bioavailability than hepatic glucuronidation metabolism. It has been reported that UDP-glucuronosyltransferase (UGT) 1A1, UGT1A8, UGT1A9, and UGT1A10 are enzymes for raloxifene glucuronidation, and UGT1A8 and UGT1A10 are absent in the human liver, whereas UGT1A1, UGT1A8, UGT1A9, and UGT1A10 are present in the human intestine. Therefore, it is also suggested that intestinal glucuronidation catalyzed by UGTs, particularly UGT1A8 and UGT1A10, may play important roles in the first-pass metabolism, causing low oral bioavailability.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>19486934</pmid><doi>10.1016/j.ijpharm.2009.05.044</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-5173 |
| ispartof | International journal of pharmaceutics, 2009-08, Vol.378 (1), p.140-141 |
| issn | 0378-5173 1873-3476 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733570991 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Oral Biological and medical sciences Biological Availability General pharmacology Glucuronidation metabolism Glucuronides - metabolism Glucuronosyltransferase - metabolism Humans Intestines - enzymology Intestines - metabolism Liver - enzymology Liver - metabolism Medical sciences Oral bioavailability Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Presystemic intestinal availability Presystemic metabolism Raloxifene Hydrochloride - pharmacokinetics Selective Estrogen Receptor Modulators - pharmacokinetics |
| title | Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T13%3A42%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intestinal%20glucuronidation%20metabolism%20may%20have%20a%20greater%20impact%20on%20oral%20bioavailability%20than%20hepatic%20glucuronidation%20metabolism%20in%20humans:%20A%20study%20with%20raloxifene,%20substrate%20for%20UGT1A1,%201A8,%201A9,%20and%201A10&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Mizuma,%20Takashi&rft.date=2009-08-13&rft.volume=378&rft.issue=1&rft.spage=140&rft.epage=141&rft.pages=140-141&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/j.ijpharm.2009.05.044&rft_dat=%3Cproquest_cross%3E733570991%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733570991&rft_id=info:pmid/19486934&rft_els_id=S0378517309003536&rfr_iscdi=true |